Ann: FDA Grants Orphan Drug Designation for Revascor, page-131

Yep. I've found that using the knowledge from my professional training allows me to invest in healthcare technology wisely and recognise potential winners like PNV relatively early. The other part is knowing when to invest aggressively and when to just stand back and look for new candidates. I have a few on my list of investments that have been up and down a lot, but are still progressing towards serious commercial recognition with far better pedigree and chances of success than Mesoblast. I top up when they are attractively priced. IMO MSB should have a market cap of maybe $25m. It'll probably end up around there eventually if it survives.

The truth is that MSB is very far down the list of where I might be interested in putting my money and there are so many better opportunities in the market, and the management is untrustworthy to boot.